Advertisement

Value Chain and CSR of Global Pharmaceutical Companies: A Framework to Define Practices

  • Nathalie Gimenes
  • Marielle A. Payaud
Chapter
Part of the Palgrave Studies in Governance, Leadership and Responsibility book series (PSGLR)

Abstract

This chapter looks at the manner in which global pharmaceutical companies contribute to a better society. To answer this, the authors constructed a framework that allows the responsible practices deployed by the global pharmaceutical companies to be identified along the value chain. This framework offers a heuristic reasoning to facilitate the understanding of the cooperative strategies used by firms and describes the social obligations which companies think they must assume toward society. It is applied through an exploratory study filled with qualitative data obtained through corporate social responsibility (CSR) reports from 2013 of global pharmaceutical companies. At the end, the chapter offers examples from these companies to describe their CSR projects and derives an overall picture of pharmaceutical companies’ contribution toward society in the post-financial crisis.

Keywords

CSR Framework Partnerships Pharmaceutical companies Value chain 

References

  1. Acquier, A., Daudigeos, T., & Valiorgue, B. (2011). Corporate social responsibility as an organizational and managerial challenge: The forgotten legacy of the corporate social responsiveness movement. M@ N@ Gement, 14(4), 222–250.AstraZeneca. (2013). AstraZeneca CSR Report. Retrieved September 15, 2014, from http://astrazeneca-annualsreport.com/2013/Google Scholar
  2. Bergouignan, B., Claude, M., Montalban, M., Sakinç, M. E., & Smith, A. (2014). L’industrie pharmaceutique Régles, acteurs et pouvoir. Paris: La ducumentation Française.Google Scholar
  3. Boidin, B., & Lesaffre, L. (2011). L’accès Des Pays Pauvres Aux Médicaments et La Propriété Intellectuelle: Quel Apport Des Partenariats Multiacteurs? Revue Internationale de Droit économique, 24(3), 325–350.Burell, G., & Morgan, G. (1979). Sociological Paradigms and Organization Analysis. Elements of Sociology of Corporate Life. Newcastle: Athenaeum Press.Google Scholar
  4. Capron, M., & Quairel-Lanoizelée, F. (2004). Mythes et réalités de L’entreprise responsable. Paris: La Découverte.Google Scholar
  5. Cavazzana-Calvo, M., & Debiais, D. (2011). Biomédicament, économie et innovation. Paris: Presses universitaires de France.Google Scholar
  6. Donation Mectizan® Program. (2013). Donation Mectizan ® Program 2013. Retrieved July 14, 2015, from http://www.mectizan.org/
  7. Gateaux, V., & Heitz, J.-M. (2008). L’accès Aux Médicaments: Un Défi Pour L’industrie Pharmaceutique. Humanisme et Entreprise, 286(1), 13–28.CrossRefGoogle Scholar
  8. Gond, J.-P. (2011). La Responsabilité Sociale de L’entreprise Au-Delà Du Fonctionnalisme: Un Cadre D’analyse Pluraliste de L’interface Entreprise-Société. Revue Finance Contrôle Stratégie, 14(2), 37–66.Google Scholar
  9. Gond, J.-P., & Igalens, J. (2014). La Responsabilité Sociale de L’entreprise. Paris: Presses universitaires de France.Google Scholar
  10. GSK. (2013b). GSK CSR report. Retrieved September 15, 2014, from http://www.gsk.com/media/325156/annual-report-2013.pdf
  11. Hoffmann, G., & Saulquin, J.-Y. (2009). Quand La RSE Revisite La Chaîne de Valeur. Management & Avenir, 28, 37–55.CrossRefGoogle Scholar
  12. Jenkins, H. (2009). A “business opportunity” model of corporate social responsibility for small-and medium-sized enterprises. Business Ethics: A European Review, 18(1), 21–36.CrossRefGoogle Scholar
  13. Johnson and Johnson. (2013a). Johnson and Johnson CSR report. Retrieved July 13, 2014, from http://www.jnj.com/sites/default/files/pdf/cs/2013-JNJ-Citizenship-Sustainability-Report-FINAL061914.pdf
  14. Johnson and Johnson. (2013b). The patient assistance program JNJ. Retrieved July 13, 2014, from http://www.jjpaf.org/
  15. Lewis, M. W., & Grimes, A. I. (1999). Metatriangulation: Building theory from multiple paradigms. Academy of Management Review, 24(4), 672–690.Google Scholar
  16. Lilly. (2013). Lilly CSR report. Retrieved October 13, 2014, from http://www.lilly.com/Documents/Lilly_2012_2013_CRreport.pdf
  17. Martinet, A. C. (1984). Management Stratégique: Organisation et Politique. Paris: McGraw-Hill.Google Scholar
  18. Martinet, A. C. (2006). Parties Prenantes, Management Stratégique et Politique. In M. Bonnafous-Boucher & Y. Pesqueux (Eds.), Décider Avec Les Parties Prenantes (pp. 9–18). Paris: La Découverte.Google Scholar
  19. Martinet, A. C., & Payaud, M. A. (2008). Formes de RSE et Entreprises Sociales. Une Hybridation Des Stratégies. Revue Française de Gestion, 180, 199–214.CrossRefGoogle Scholar
  20. Martinet, A. C., & Payaud, M. A. (2009). Un Cadre Théorique Intégrateur Pour Le Management Stratégique «BOP». Revue de l’Organisation Responsable, 4, 19–30.CrossRefGoogle Scholar
  21. Martinet, A. C., & Payaud, M. A. (2010). La Stratégie BOP à L’épreuve Des Pauvretés. Une Modélisation Dialogique. Revue Française de Gestion, 36(208–209), 63–81.CrossRefGoogle Scholar
  22. Merck & Co. 2014. Merck & Co website. Retrieved September 15, from http://www.merck.com
  23. Mills, A. (2002). La Science et La Technologie En Tant Que Biens Publics Mondiaux: S’attaquer Aux Maladies Prioritaires Des Pays Pauvres. Revue D’économie Du Développement, 16(1), 117–139.CrossRefGoogle Scholar
  24. Novartis. (2013). Novartis CSR report. Retrieved January 28, 2014, from https://www.novartis.com/corporate-responsibility/metrics-and-reporting/cr-performance-report.shtml
  25. Novartis. (2015). Novartis website. Retrieved July 15, from https://www.novartis.com/about-us/corporate-responsibility
  26. Palazzo, G., & Wentland, M. (2011). Evaluation de la performance sociale et environnementale des entreprises. Retrieved July 15, 2015, from http://www.unil.ch/files/live//sites/unicom/files/shared/pdfs/etude.pdf
  27. Pfizer. (2013). ProgramRxPathways TM. Retrieved September 20, 2014, from http://www.pfizerrxpathways.com
  28. PWC. (2013). Rapport 686. Développement Durable Pharmaceutique. Retrieved July 15, 2015, from http://developpement-durable.pwc.fr/fr/approche-par-secteur-d-activite/secteur-pharmaceutique/
  29. Roche. (2013a). Roche CSR report. Retrieved July 30, 2014, from http://www.roche.com/gb13e.pdf
  30. Roche. (2013b). Roche website. Retrieved December 22, from http://www.roche.com/sustainability.htm
  31. Sanofi. (2013). Sanofi CSR report. Retrieved May 6, 2014, from http://www.sanofi.com/Images/36400_Rapport_RSE_2013.pdf
  32. Schneider, J. L., Wilson, A., & Rosenbeck, J. M. (2010). Pharmaceutical companies and sustainability: An analysis of corporate reporting. Benchmarking: An International Journal, 17(3), 421–434.CrossRefGoogle Scholar
  33. Teva. (2013). Teva CSR report. Retrieved April 14, 2014, from http://www.teva-csr-report-2013.com/
  34. Turcotte, M.-F. B., & Pasquero, J. (2007). L’industrie Pharmaceutique et Ses Responsabilités Sociales. In J. J. Levy & C. Garnier (Eds.), La Chaine Des Medicaments: Perspectives Pluridisciplinaires (pp. 200–257). Quebec: Presses de l’Université du Quebec.Google Scholar
  35. Vogel, D. (2006). The market for virtue: The potential and limits of corporate social responsibility. Virginia: Brookings Institution Press.Google Scholar
  36. WHO. (2013). Global programme to eliminate lymphatic filariasis. Retrieved July 15, 2015, from http://www.who.int/lymphatic_filariasis/en/

Copyright information

© The Author(s) 2017

Authors and Affiliations

  • Nathalie Gimenes
    • 1
  • Marielle A. Payaud
    • 1
  1. 1.IAE Lyon—Université Jean Moulin Lyon 3Centre de Recherche MagellanLyon cedex 08France

Personalised recommendations